Modulators of THR-β and methods of use thereof

In the United States alone, NASH is the third most common indication for liver transplantation and is on track to become the most common [4]. The greatest medical need in patients with NAFLD and NASH is effective therapies to halt progression and potentially reverse fibrosis, the primary predictor …